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Aims The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spon-
taneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac bio-
markers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass
surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–
kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY
OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coron-
ary syndrome (ACS) and elevated LDL-C (>_1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis,
we assessed the effects of alirocumab on types of MI.
...................................................................................................................................................................................................
Methods
and results
Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860
total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events
were Type 3 (n= 2) or Type 5 (n= 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence inter-
val (CI) 0.77–0.95; P= 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P= 0.032) and Type 2
(0.77, 0.61–0.97; P= 0.025), but not Type 4 MI.
...................................................................................................................................................................................................
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Conclusion After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indi-
cate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein
cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.
                                                                                                                                                                                                                   
Keywords Alirocumab • Prevention • MI types • Mortality
Introduction
Lowering of low-density lipoprotein cholesterol (LDL-C) with statins
by 1 mmol/L (39 mg/L) is associated with an approximate 20% reduc-
tion in the rate of myocardial infarction (MI).1 The proprotein con-
vertase subtilisin–kexin Type 9 (PCSK9) inhibitors evolocumab and
alirocumab reduce LDL-C by >1 mmol/L below statin-treated levels
and further reduce the risk of MI among patients treated with
statins.2,3
In 2007, the Universal Definition of MI Task Force introduced a
classification of five types of MI based on presumptive mechanisms,
including Type 1 due to spontaneous plaque rupture or fissuring with
thrombus, Type 2 due to myocardial supply and/or demand imbal-
ance, Type 3 with cardiac death suggestive of MI without biomarker
elevation, Type 4 related to percutaneous coronary intervention
(PCI), and Type 5 related to coronary artery bypass grafting
(CABG).4 In the FOURIER trial,5 which randomized stable patients
with a history of MI, stroke, or peripheral vascular disease, evolocu-
mab reduced the number of MIs vs. placebo. Evolocumab reduced
the number of Type 1 and Type 4 MIs, but not Type 2 MIs.
In this pre-specified analysis from the ODYSSEY OUTCOMES
trial, we studied the occurrence and outcomes of the different types
of MIs in patients with recent acute coronary syndrome (ACS) and
elevated LDL-C despite intensive statin therapy who were random-
ized to receive alirocumab or placebo and followed for cardiovascu-
lar outcomes.
Methods
The study design6 and primary results3 have been published. Qualifying
patients were >_40 years, provided written informed consent, had been
hospitalized with ACS (acute MI or unstable angina) 1–12 months before
randomization, and had an LDL-C level >_1.81 mmol/L (70 mg/dL), non-
high-density lipoprotein cholesterol (non-HDL-C) >_2.59 mmol/L
(100 mg/dL), or apolipoprotein B >_2.07 mmol/L (80 mg/dL), measured
after >_2 weeks of stable treatment with atorvastatin 40–80 mg daily,
rosuvastatin 20–40 mg daily, or the maximum-tolerated dose of either
statin (including no statin in case of documented intolerance).
Randomization (1:1) to treatment with alirocumab 75 mg or matching
placebo, stratified by country, was performed, with 18 924 patients meet-
ing the entry criteria. Study medication was given by subcutaneous injec-
tion every 2 weeks. The dose of alirocumab was adjusted under blinded
conditions to target an LDL-C level of 0.6–1.3 mmol/L (details on the
dosing strategy are provided in Supplementary material online, Text S1).
The primary composite endpoint was death due to coronary heart
disease, non-fatal MI, fatal and non-fatal ischaemic stroke, or unstable an-
gina requiring hospitalization. The incidence of MI was defined as the
time to first occurrence of MI. In a pre-specified analysis, the types of MI
were defined according to the Third Universal Definition7 and were
adjudicated by a central clinical events committee blinded to the treat-
ment assignment and lipid levels. Biomarker measurements were not
mandated after PCI or CABG. The definitions of Type 1 and Type 2 MIs
are detailed in Supplementary material online, Tables S1 and S2.
Predictors of Type 1 and Type 2 MI and total mortality after MI were
assessed. Silent MIs were not included.
Statistical analysis
Continuous variables are expressed as median (quartile 1–quartile 3) and
categorical variables as count (percentage). Comparisons of baseline
characteristics grouped by type of first MI during follow-up (none, Type
1, or Type 2) were by the Wilcoxon rank-sum tests for continuous varia-
bles and the v2 and Fisher’s exact tests (where possible) for categorical
variables. For all analyses, P-values <0.05, two-tailed, were considered
statistically significant, with no adjustment for multiple testing.
The treatment effect on time to first MI of any type and time to first
Type 1, 2, or 4 MI was initially assessed in Cox proportional hazard
models, with stratification by geographic region; competing risk analyses
with all-cause death as the competing event were performed as sensitiv-
ity analyses.8 Multivariable Cox regression models of baseline demo-
graphics and clinical characteristics (candidate variables are listed in
Supplementary material online, Tables S3 and S4) to predict Type 1 or
Type 2 MI were then determined by stepwise selection, with P-value
<0.05 for model entry or exit. Models to estimate the associations
between all-cause and cause-specific (cardiovascular or non-
cardiovascular) death and incident Type 1 or Type 2 MI as a time-
varying covariate were determined, with adjustment for treatment as-
signment and baseline covariates previously determined to be prognos-
tic for survival.9 The effects of treatment assignment on death before or
after a Type 1 or Type 2 MI were determined in separate Cox regres-
sion models for each MI type by interactions between incident MI as a
time-varying covariate and treatment, with stratification by geographical
region. For a given patient, an MI that occurred on the same day as death
was excluded from the analysis. Sensitivity analyses of time to MI
included events on the same day as death.
All analyses were conducted according to intention-to-treat, including
all patients and events from randomization to common study end date
(11 November 2017). Unless otherwise indicated, analyses were pre-
specified before unblinding of the study database. Analyses were per-
formed in SAS 9.4 and Sþ 8.2.
Results
A total of 18 924 patients were randomized at 1315 sites in 57 coun-
tries, with 9462 patients assigned to alirocumab and 9462 patients to
placebo. Median follow-up was 2.8 (2.3–3.4) years. A total of 1860
post-randomization MIs occurred in 1383 (7.3%) patients. Of these,
991 patients had a total of 1223 Type 1 MIs, 287 patients had 386
Type 2 MIs, 225 patients had 244 Type 4 MIs, and a remaining 7
patients had Type 3 or Type 5 MIs. The baseline characteristics of the
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.patients without an MI, and with Type 1 or Type 2 MI, are detailed in
Table 1 and Supplementary material online, Table S5. Compared to
patients without an MI, those with an MI were older and the propor-
tion of women was greater. Compared to patients with a first
post-randomization event of Type 1 MI, patients with a first post-
randomization event of Type 2 MI were older, more likely to be from
North America, to have a lower glomerular filtration rate, and were
more likely to have a history of hypertension, heart failure, chronic
....................................................................................................................................................................................................................
Table 1 Selected baseline characteristics of patients with Type 1 and 2 myocardial infarctions
(A) No event
(N5 17 719)
(B) First
event5Type 1
(N5 963)
(C) First
event5Type 2
(N5 242)
P-value for (A) vs.
(B) vs. (C)a
P-value for
(B) vs. (C)b
Age (years) 58 (52–65) 59 (52–66) 65 (59–72) <0.0001 <0.0001
Women 4416 (24.9) 267 (27.7) 79 (32.6) 0.004 NS
Race <0.0001 NS
White 14 039 (79.2) 788 (81.8) 197 (81.4)
Asian 2390 (13.5) 86 (8.9) 22 (9.1)
Black 411 (2.3) 44 (4.6) 18 (7.4)
Other 879 (5.0) 45 (4.7) 5 (2.1)
Region of enrolment <0.0001 0.029
Western Europe 3894 (22.0) 232 (24.1) 49 (20.2)
Eastern Europe 5185 (29.3) 199 (20.7) 53 (21.9)
North America 2555 (14.4) 234 (24.3) 82 (33.9)
South America 2469 (13.9) 103 (10.7) 16 (6.6)
Asia 2194 (12.4) 80 (8.3) 19 (7.9)
Rest of world 1422 (8.0) 115 (11.9) 23 (9.5)
Medical history before index ACS
Hypertension 11 277 (63.6) 758 (78.1) 214 (88.4) <0.0001 0.0005
Diabetes 4924 (27.8) 404 (42.0) 116 (47.9) <0.0001 NS
Current smoker 4261 (24.0) 252 (26.2) 47 (19.4) NS 0.0305
MI 3174 (17.9) 373 (38.7) 92 (38.0) <0.0001 NS
PCI 2805 (15.8) 347 (36.0) 89 (36.8) <0.0001 NS
CABG 844 (4.8) 162 (16.8) 41 (16.9) <0.0001 NS
Stroke 541 (3.1) 55 (5.7) 15 (6.2) <0.0001 NS
Malignant disease 475 (2.7) 36 (3.7) 21 (8.7) <0.0001 0.0033
COPD 637 (3.6) 68 (7.1) 41 (16.9) <0.0001 <0.0001
Peripheral artery disease 628 (3.5) 89 (9.2) 42 (17.4) <0.0001 0.0007
Heart failure 2542 (14.3) 195 (20.2) 78 (32.2) <0.0001 0.0001
Index ACS <0.0001 NS
NSTEMI 8443 (47.7) 587 (61.0) 145 (59.9)
STEMI 6209 (35.1) 259 (26.9) 68 (28.1)
Unstable angina 3037 (17.2) 116 (12.1) 29 (12.0)
PCI or CABG for index ACS 12 886 (72.7) 630 (65.4) 161 (66.5) <0.0001 NS
GFR (mL/min/1.73 m2) 79 (68–90) 76 (63–88) 67 (54–84) <0.0001 <0.0001
GFR <60 mL/min/1.73 m2 2256 (12.7) 199 (20.7) 84 (34.7) <0.0001 <0.0001
Time from index ACS to randomization (months) 2.6 (1.7–4.4) 2.5 (1.7–3.9) 2.5 (1.7–4.2) 0.037 NS
Body mass index (kg/m2) 28 (25–31) 29 (26–32) 29 (26–33) <0.0001 NS
LDL-C (mg/dL) 86 (73–103) 91 (76–113) 91 (75–109) <0.0001 NS
LDL-C >_100 mg/dL 5177 (29.2) 365 (37.9) 87 (36.0) <0.0001 NS
Triglycerides (mg/dL) 128 (94–181) 138 (100–201) 130 (90–178) <0.0001 0.012
Lipoprotein(a) (mg/dL) 20.8 (6.6–59.0) 25.4 (7.3–70.0) 34.9 (9.3–76.8) <0.0001 NS
Randomized to placebo 8808 (49.7) 512 (53.2) 142 (58.7) 0.003 NS
Data are represented as median (quartile 1–quartile 3) or n (%). Additional information on baseline characteristics is presented in Supplementary material online, Table S5.
aRank-based tests, comparing A vs. B vs. C.
bRank-based test, comparing B vs. C.
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; LDL-C, low-density
lipoprotein cholesterol; MI, myocardial infarction; NS, not significant; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention;
STEMI, ST-segment elevation myocardial infarction.
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.obstructive pulmonary disease, peripheral artery disease, or malig-
nant disease, and were less likely to be smokers. Baseline LDL-C, lip-
oprotein(a), and high-sensitivity C-reactive protein levels were
higher in patients with than without MI. Baseline LDL-C, lipopro-
tein(a), and high-sensitivity C-reactive protein did not differ between
those with Type 1 or Type 2 MI. Triglyceride levels were higher at
baseline in patients who had MIs compared with those not having
MIs, and patients with Type 2 MIs had lower triglyceride levels than
patients with Type 1 MIs (P= 0.012).
Mean LDL-C levels were reduced by 54% with alirocumab vs. pla-
cebo, from 2.39 mmol/L (92 mg/dL) to 1.24 mmol/L (48 mg/dL), at
12 months. Alirocumab reduced the occurrence of post-
randomization MI vs. placebo [6.8% vs. 7.9%; hazard ratio (HR) 0.85,
95% confidence interval (CI) 0.77–0.95; P= 0.003]. Both Type 1 MIs
(P= 0.032) and Type 2 MIs (P= 0.025) were reduced with alirocumab
(Table 2). There was no apparent effect on Type 3, 4, or 5 MIs.
Take home figure shows the Kaplan–Meier curve of the occurrence
of Type 1 and Type 2 MIs after randomization by treatment group. A
benefit of alirocumab treatment on Type 1 MI was apparent after
year 1 and increased after year 2, whereas the treatment effect on
Type 2 MI appeared more constant over time (Figure 1). These
observations are supported by post hoc model results: allowing the
treatment HR to change for each of the time intervals indicated in
Figure 1 fit the data better than a constant HR for Type 1 MI
(P= 0.05) but not for Type 2 MI (P= 0.34).
Most MIs (82.7%) were non-ST-segment elevation MI (non-
STEMI) and were significantly reduced with alirocumab (HR 0.82,
95% CI 0.72–0.93; P= 0.002). There were consistent effects on
STEMIs. Q-wave MIs were identified in a minority (10.5%) of patients
with interpretable electrocardiograms (ECGs), with consistent
effects of alirocumab for Q-wave and non-Q-wave MIs (Table 2).
A sensitivity analysis including patients who died on the day of MI
(n= 7 alirocumab; n= 11 placebo) showed similar effects of alirocu-
mab on reducing both Type 1 and Type 2 MIs (Supplementary mater-
ial online, Table S6).
Supplementary material online, Table S7 shows the effect of aliro-
cumab on biomarker levels, predominantly cardiac troponin (92%)
and high-sensitivity troponins (29%), at various cut-points.
Alirocumab treatment was associated with no apparent reduction in
smaller MIs (with peak biomarker levels <3 times the upper limit of
normal) but with large reductions in larger MIs as defined by peak
biomarker value.
............................................. .............................................
....................................................................................................................................................................................................................
Table 2 Types of myocardial infarctions and effects of alirocumab
Alirocumab Placebo Treatment
HR (95% CI)a
P-valuea
Patients
with MI,a n (%)
Total MIs Patients
with MI,a n (%)
Total MIs
Any MI 639 (6.8) 866 744 (7.9) 994 0.85 (0.77–0.95) 0.003
Universal classification
Type 1b 463 (4.9) 560 528 (5.6) 663 0.87 (0.77–0.99) 0.032
Type 2c 125 (1.3) 180 162 (1.7) 206 0.77 (0.61–0.97) 0.025
Type 3d 2 (<0.1) 2 0 0 – –
Type 4Ae 22 (0.2) 23 28 (0.3) 29 0.94 (0.72–1.22)f 0.62
Type 4Bg 50 (0.5) 55 46 (0.5) 49
Type 4Ch 37 (0.4) 44 42 (0.4) 44
Type 5i 2 (<0.1) 2 3 (<0.1) 3 – –
ECG classification
NSTEMI 437 (4.6) 576 529 (5.6) 692 0.82 (0.72–0.93) 0.002
STEMI 92 (0.5) 96 109 (1.2) 116 0.84 (0.64–1.11) 0.22
ECG not interpretable or not available 161 (1.7) 194 162 (1.7) 186 1.01 (0.81–1.25) 0.96
Q-wave classification
Q-wave 52 (0.5) 52 71 (0.9) 73 0.73 (0.51–1.04) 0.08
Non-Q-wave 483 (5.1) 634 560 (5.9) 725 0.86 (0.76–0.97) 0.013
ECG not interpretable or available 146 (1.5) 180 165 (1.7) 196 0.88 (0.71–1.10) 0.27
aAnalysis of time to first Type 1, Type 2, or Type 4A, 4B, 4C MI by Cox proportional hazards models, stratified by geographical region.
bSpontaneous.
cSupply/demand imbalance.
dCardiac death suggestive of MI without increased biomarkers.
ePeri-percutaneous coronary intervention.
fCorrespond to any Type 4 MI.
gStent thrombosis.
hRestenosis.
iPeri-coronary artery bypass grafting.
CI, confidence interval; ECG, electrocardiogram; HR, hazard ratio; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial
infarction.
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myocardial infarction
Tables 3 and 4 and Supplementary material online, Figure S1 show the
independent predictors for Type 1 and Type 2 MIs, respectively.
Most of the factors predicting occurrence of Type 1 or Type 2 MI
were similar. Of note, baseline LDL-C was an independent predictor
of occurrence of Type 1 but not Type 2 MI. Similarly, previous
CABG, revascularization at the time of the index ACS event, current
smoking, and previous stroke were significant predictors of occur-
rence of subsequent Type 1 MI but not Type 2 MI. Conversely, age
(by discrete categories), history of chronic obstructive pulmonary
disease, and lower baseline HDL-C levels were significant predictors
of Type 2 but not Type 1 MI. Race, history of diabetes, hypertension,
and peripheral artery disease were risk factors for both types of MI.
Randomization to alirocumab was associated with lower risk of both
types of MI.
Mortality in patients with Type 1 or Type
2 myocardial infarction
During 1.6 (0.8–2.4) and 1.3 (0.5–2.3) years of follow-up following
Type 1 and Type 2 MI, respectively, mortality following the occur-
rence of Type 2 MI (n= 73, 25.4%) was more than double that of
patients with Type 1 MI (n= 118, 11.9%). In post hoc analyses, rates of
death were 10.2% with alirocumab vs. 13.4% with placebo (HR 0.69,
95% CI 0.48–1.00) following Type 1 MI and 24.8% vs. 25.9% (HR
0.98, 95% CI 0.62–1.56) following Type 2 MI.
Discussion
After an index ACS, there is a substantial incidence of recurrent MI.
In the placebo group of the ODYSSEY OUTCOMES trial, this
incidence was 7.9% over a median follow-up of 2.8 years, despite
Figure 1 Treatment effect of alirocumab categorized according to the time between randomization and the first occurrence of myocardial infarc-
tion. CI, confidence interval; HR, hazard ratio; MI, myocardial infarction.
Take home figure Kaplan–Meier curves for the first occurrence of Type 1 and Type 2 myocardial infarctions and the effects of alirocumab
over time. MI, myocardial infarction.
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high-intensity statin treatment and high use of other evidence-based
therapies. The rate of Type 1 MI was more than double that of all
other types combined. Alirocumab treatment reduced the overall in-
cidence of MI, an observation that appears driven by a reduction in
both Type 1 and Type 2 MIs. The treatment benefit on Type 1 MI
increased with time elapsed since randomization, suggesting that
treatment benefit may increase with longer treatment duration. The
finding that a lipid-lowering treatment could reduce the incidence of
Type 2 MI is novel. The benefit of alirocumab on reducing both types
of MI was more pronounced when biomarker elevation, as a measure
of infarct size, exceeded three times the upper limit of normal.
It is unlikely that the reduced occurrence of Type 2 MI with aliro-
cumab treatment resulted from an effect on myocardial oxygen de-
mand. However, alirocumab treatment may have improved
myocardial oxygen supply. In the GLAGOV trial,10 evolocumab treat-
ment added to statin treatment in patients with coronary artery dis-
ease (CAD) produced substantial further lowering of LDL-C and
reduced the volume of coronary artery plaque within 18 months,
compared with placebo. In the current study, alirocumab reduced
LDL-C levels by 54% from baseline to 12 months. Alirocumab may
therefore have had similar effects in ODYSSEY OUTCOMES in pre-
venting plaque progression or promoting plaque regression, resulting
in greater capacity for myocardial oxygen delivery and consequently
a lower risk of Type 2 MI. It is not known whether PCSK9 inhibitors
have favourable effects on coronary endothelial or microvascular
function.
The incidence of Type 2 MI as a proportion of total MIs has varied
from around 1.6% to 29.6% in randomized trials and population stud-
ies.11 Here, the incidence was in the higher portion of that range. In
this trial, potent lipid-lowering with alirocumab reduced the occur-
rence of Type 2 MI. To our knowledge, this is the first such observa-
tion and contrasts with the lack of effect on Type 2 MI seen in the
FOURIER trial.5 The reason for this contrast is unknown, but could
be related to differences in patient populations, number of events,
duration of follow-up, definitions, and adjudication processes.
Specifically, the ODYSSEY OUTCOMES trial included high-risk
patients with recent ACS rather than stable patients with a history of
MI, stroke, or peripheral vascular disease, and they were followed for
longer (2.8 vs 2.2 years in the FOURIER trial5). Differences between
.................................................................................................
Table 3 Independent predictors of Type 1 myocardial
infarction following initial acute coronary syndrome
Baseline characteristics HR (95% CI) P-value
Medical history
Peripheral artery disease 1.61 (1.29–2.00) <0.0001
Percutaneous coronary intervention 1.51 (1.27–1.79) <0.0001
CABG 1.74 (1.45–2.09) <0.0001
Diabetes 1.57 (1.38–1.79) <0.0001
Current smoker 1.23 (1.06–1.42) 0.006
Hypertension 1.54 (1.31–1.81) <0.0001
MI 1.46 (1.23–1.74) <0.0001
Heart failure 1.33 (1.12–1.57) 0.001
Stroke 1.34 (1.02–1.75) 0.034
Region <0.0001
Western Europe Reference
Eastern Europe 0.50 (0.41–0.61)
North America 0.93 (0.77–1.13)
South America 0.65 (0.51–0.84)
Asia 2.03 (0.97–4.26)
Rest of world 1.16 (0.92–1.46)
LDL-C per 1 mmol/L increment 1.19 (1.11–1.27) <0.0001
GFR <60 mL/min/1.73 m2 1.37 (1.17–1.60) 0.0001
Revascularization for index event 0.80 (0.70–0.91) 0.0009
Race 0.009
White Reference
Asian 0.38 (0.19–0.77)
Black 1.37 (1.01–1.87)
Other 0.97 (0.70–1.33)
Alirocumab treatment 0.87 (0.77–0.99) 0.029
CABG, coronary artery bypass grafting; CI, confidence interval; GFR, glomerular
filtration rate; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; MI,
myocardial infarction.
.................................................................................................
Table 4 Independent predictors of Type 2 myocardial
infarction following initial acute coronary syndrome
Baseline characteristics HR (95% CI) P-value
Medical history
Peripheral artery disease 2.49 (1.83–3.39) <0.0001
Percutaneous coronary intervention 1.48 (1.09–2.01) 0.012
COPD 2.26 (1.63–3.15) <0.0001
Heart failure 2.36 (1.80–3.09) <0.0001
Diabetes 1.76 (1.38–2.25) <0.0001
Hypertension 2.66 (1.79–3.97) <0.0001
MI 1.49 (1.11–2.01) 0.009
Region <0.0001
Western Europe Reference
Eastern Europe 0.45 (0.30–0.65)
North America 1.16 (0.83–1.64)
South America 0.44 (0.25–0.76)
Asia 1.23 (0.36–4.21)
Rest of world 1.22 (0.77–1.94)
HDL-C per 1 mg/dL increment 1.01 (1.00–1.02) 0.017
GFR <60 mL/min/1.73 m2 2.05 (1.57–2.67) <0.0001
Age category <0.0001
<65 years Reference
65 to <75 years 1.46 (1.11–1.91)
>_75 years 2.26 (1.58–3.23)
Race 0.021
White Reference
Asian 0.76 (0.24–2.36)
Black 1.92 (1.22–3.02)
Other 0.62 (0.27–1.45)
Alirocumab treatment 0.77 (0.61–0.97) 0.029
CI, confidence interval; COPD, chronic obstructive pulmonary disease; GFR,
glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HR, haz-
ard ratio; MI, myocardial infarction.
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the studies in the effects of treatment with a PSCK9 inhibitor on spe-
cific types of MI might also be related to differences in prevailing bio-
marker assays, and cut-off values.
Some reports ascertaining the incidence of Type 2 MI have used
specific defined oxygen supply/demand mismatch criteria,11,12 where-
as others have used more liberal criteria.13 The ischaemic thresholds
for myocardial oxygen supply/demand imbalance vary markedly in re-
spect to the magnitude of the stressor and the amount of underlying
CAD.14 Most studies have shown a higher frequency of Type 2 MI in
patients with comorbid conditions. Similarly, we found that patients
with Type 2 MI were more likely than patients with Type 1 MI to
have comorbidities including hypertension, heart failure, chronic ob-
structive pulmonary disease, diabetes, or malignancy. The rate of
STEMI was relatively high in patients with Type 2 MI, but was similar
to patients with Type 1 MI (28.1% vs. 26.9%). Reported rates of
STEMI in patients with Type 2 MI have ranged from 3.4% to 9.7%.11,13
Some of the patients in the present study with STEMI and Type 2 MI
may have had plaque rupture with thrombus formation or emboliza-
tion of thrombus, which may have been missed on angiography be-
cause of the low sensitivity for detecting thrombus, including beyond
the plaque rupture in the proximal epicardial coronary vessel. Also,
some of these patients may have had coronary artery spasm causing
transmural ischaemia and STEMI.
The short- and long-term mortality rates for patients with Type 2
MI are generally higher than for Type 1 MI patients in most studies,
due to an increased prevalence of comorbid conditions.11–13,15–20
However, adjusted mortality may be similar.13 Here, we found all-
cause death to be more than twice as high after Type 2 than Type 1
MI.
The presence of significant CAD is a common finding in patients
with Type 2 MI selected to undergo coronary angiography. The inci-
dence of CAD depends on the population and how intensively they
are studied. The presence of CAD in Type 2 MI ranges from 55% to
68%.13,21,22 In general, patients with Type 2 MI and CAD have a
worse prognosis than those without CAD.18,20,22 As patients in the
present study all had a recent ACS (within the past 1–12 months), it
is likely that most had significant CAD and many would have bene-
fited from lipid-lowering therapy through a decrease in plaque lipid
content, and inflammatory cells perhaps leading to improved plaque
stability and decreased progression of atherosclerosis. There are no
data that statins or PCSK9 inhibitors modulate the risk associated
with erosions. It is possible that Alirocumab by reducing LDL-C could
improve coronary endothelial function.23
In the FOURIER trial, evolocumab reduced Type 4 MI (n= 194).5
However, in this trial we found no effect of alirocumab on reducing
Type 4 MI despite a similar number of events (n= 225) as in the
FOURIER trial. Several small trials have suggested that statin loading
before PCI may reduce the occurrence of Type 4 MI.24 However, the
recent large randomized SECURE-PCI trial showed that two loading
doses of 80 mg atorvastatin before and 24 h after a planned PCI had
no effect on a composite of death, MI, stroke, or unplanned coronary
revascularization.25 Our observations are consistent with the latter
trial with no apparent effect of alirocumab on reducing Type 4a, 4b,
or 4c MI, with 109 events occurring with alirocumab and 116 with
placebo.
We pre-specified five geographic regions for the 57 participating
countries (Supplementary material online, Table S8). Regional analysis
showed that Type 2 MIs were relatively more frequent in North
America (ratio of Type 2 to Type 1 MI 0.35) than in South America,
Asia, and the rest of the world (ratio of Type 2 to Type 1 MI 0.16,
0.24, and 0.20, respectively). These findings could reflect regional dif-
ferences in patient baseline characteristics or prevailing practice pat-
terns influencing the ascertainment of electrocardiographic, biomarker
or echocardiographic data to support MI diagnosis.
The prevalent use of therapies well-established to reduce the risk
of recurrent MI were examined according to type of MI. Beta-blocker
use at randomization was high and similar in patients who subse-
quently had Type 1 or Type 2 MI (86.5% vs. 85.1%, respectively).
Large majorities of the patients with either Type 1 or Type 2 MI were
treated with aspirin (94.5% and 89.3%, respectively).
Limitations
We did not specify study-specific adjudication algorithms to distin-
guish Type 1 and 2 MI. The trial did not mandate routine biomarker
measurements following PCI or CABG to detect Type 4 and Type 5
MIs, and consequently there may have been under ascertainment of
those events. The absence of any alirocumab treatment effect on the
occurrence of Type 4 MI could represent Type 2 error, due to the
relatively small number of these events. Classification of MI according
to the development of Q-waves may have been limited because the
protocol did not specify ECGs at fixed times in the study and there
was no core ECG laboratory. We had no protocol-specified meas-
urement of left ventricular function to ascertain the size of the MIs in
addition to biomarker assessment. Finally, as pre-specified, we
focused on first MI after randomization rather than analysing total MI
events.9
Conclusion
In patients with ACS, alirocumab added to intensive statin therapy
during 2.8 years of follow-up reduced the occurrence of both Type 1
and Type 2 MI. For Type 1 MIs, treatment benefit appeared to in-
crease over time. The data indicate for the first time that a lipid-
lowering therapy can attenuate the risk of Type 2 MI. Therefore,
LDL-C lowering with alirocumab below levels achieved with statins
may be an important preventive treatment for both Type 1 and Type
2 MI following ACS.
Supplementary material
Supplementary material is available at European Heart Journal online.
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